San Francisco, California (PressExposure) August 30, 2011 -- Charles R. Cantor, Chief Scientific Officer at Sequenom and Member of the US National Academy of Sciences, will give a plenary keynote presentation on "Noninvasive Personalized Genomics" at the 7th Modern Drug Discovery and Development Summit to be held in San Diego, CA on October 19-21, 2011 by GTC.
Second generation DNA sequencing and DNA mass spectrometry provide complementary, synergistic ways of analyzing nucleic acids in patient samples like blood plasma that can be obtained non-invasively. Sequencing is best where large genomic regions or even the entire genome must be scanned and where the analytes of interest exist in a relatively narrow concentration range. Mass spectrometry is best where at most a few hundred loci need to be examined but high sensitivity or high dynamic range are required. Charles Cantor will show examples in a number of areas including non-invasive prenatal diagnostics by plasma analysis and detection of somatic oncogene mutations in various clinical samples. He will also describe a pilot study in which an entire fetal genome was sequenced from maternal plasma.
Dr. Charles Cantor is a founder, and Chief Scientific Officer at SEQUENOM, Inc., which is a genetics discovery company with tools, information and strategies for determining the medical impact of genes and genetic variations. He is also founder of SelectX Pharmaceuticals, a drug discovery company, Retrotope, an anti-aging company, and Dithera, a biotherapeutic company. Dr. Cantor is professor emeritus Biomedical Engineering and Pharmacology and was the director of the Center for Advanced Biotechnology at Boston University. He is adjunct professor of Bioengineering at UC San Diego, adjunct professor of Molecular Biology at the Scripps Institute for Research, and distinguished adjunct professor of Physiology and Biophysics at UC Irvine. Dr. Cantor has been granted 60 US patents and wrote a three-volume textbook on biophysical chemistry. He co-authored the first textbook on Genomics titled 'The Science and Technology of the Human Genome Project'. In addition, he sits on the advisory boards of more than 15 national and international biotechnology firms, has published more than 450 peer-reviewed articles, and is a member of the National Academy of Sciences.
The 7th Modern Drug Discovery and Development Summit will bring researchers, lab directors/managers, and industry executives the critical scientific, technology, and business coverage that they need. M3D will offer an in-depth examination of the challenges involved in the dynamic and ever-changing field of drug discovery and development. Over 125 leading industrial and academic experts will present at this three-day summit and is comprised of a half day plenary keynote session and 4 full conferences. The M3D Summit includes the following conferences:
5th Biomarker Discovery and Development
5th Drug Design and Medicinal Chemistry
5th Advances in Stem Cell Discovery and Development
4th Protein Discovery & Therapeutics
For more information, please visit http://www.gtcbio.com.